Laboratory-based biomarkers to improve causality assessment in drug-induced liver injury.
Laboratory-based biomarkers to improve causality assessment in drug-induced liver injury.
复制标题
DOI:
10.1002/cld.611
复制
发表时间:
2017-02-01
影响因子:
--
通讯作者:
Antoine, Daniel J
中科院分区:
文献类型:
--
作者:
Antoine, Daniel J
Drug-induced liver injury (DILI) represents a major medical concern associated with significant patient morbidity and mortality. Within drug development, attrition caused by DILI occurs in all phases of the pipeline, from preclinical testing to clinical trials to the marketplace. DILI is largely categorized into two major forms: intrinsic and idiosyncratic. In cases where the frequency is high in either animal species or in humans, DILI is considered intrinsic in that it is assumed to result from direct hepatocellular damage. Idiosyncratic DILI occurs rarely in susceptible individuals exposed to therapeutic doses but can represent a serious adverse drug reaction. 1 It should be considered in patients who have deranged liver function tests secondary to the administration of a potentially hepatotoxic agent. Idiosyncratic DILI is unpredictable because of the complex nature of the mechanisms of the disease.Currently, the diagnosis of DILI is based on exclusion. The exclusion of other differential causes and an understanding of the temporal relationship to the administration of a potential hepatotoxin represent the cornerstone for establishing a diagnosis of DILI. For causality assessment, different methods such as the Roussel-Uclaf Causality Assessment Method (RUCAM) or a consensusbased expert opinion approach are two main mechanisms used. 2 Despite relative strength, each mechanism is also associated with a number of limitations. A major